- Home
- MAMA vs SERA Comparison
MAMA vs SERA Comparison
Compare MAMA & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- SERA
- Stock Information
- Founded
- MAMA 2010
- SERA 2008
- Country
- MAMA United States
- SERA United States
- Employees
- MAMA N/A
- SERA N/A
- Industry
- MAMA Specialty Foods
- SERA Precision Instruments
- Sector
- MAMA Consumer Staples
- SERA Health Care
- Exchange
- MAMA Nasdaq
- SERA Nasdaq
- Market Cap
- MAMA 290.7M
- SERA 258.3M
- IPO Year
- MAMA N/A
- SERA 2021
- Fundamental
- Price
- MAMA $7.85
- SERA $6.49
- Analyst Decision
- MAMA Strong Buy
- SERA
- Analyst Count
- MAMA 4
- SERA 0
- Target Price
- MAMA $10.00
- SERA N/A
- AVG Volume (30 Days)
- MAMA 222.3K
- SERA 57.4K
- Earning Date
- MAMA 12-10-2024
- SERA 11-06-2024
- Dividend Yield
- MAMA N/A
- SERA N/A
- EPS Growth
- MAMA N/A
- SERA N/A
- EPS
- MAMA 0.13
- SERA N/A
- Revenue
- MAMA $113,593,000.00
- SERA $94,000.00
- Revenue This Year
- MAMA $18.91
- SERA N/A
- Revenue Next Year
- MAMA $12.69
- SERA $2,018.04
- P/E Ratio
- MAMA $60.01
- SERA N/A
- Revenue Growth
- MAMA 17.81
- SERA N/A
- 52 Week Low
- MAMA $3.38
- SERA $1.65
- 52 Week High
- MAMA $8.69
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- MAMA 52.82
- SERA 47.81
- Support Level
- MAMA $6.90
- SERA $7.56
- Resistance Level
- MAMA $8.57
- SERA $8.78
- Average True Range (ATR)
- MAMA 0.33
- SERA 0.58
- MACD
- MAMA -0.01
- SERA 0.03
- Stochastic Oscillator
- MAMA 74.60
- SERA 34.36
About MAMA Mama's Creations Inc.
Mama`s Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in over 8,400 grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.